In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens.
The in vitro activities of two new carboxyquinolones, A-56619 (difloxacin) and A-56620, were compared with those of ciprofloxacin, norfloxacin, and ofloxacin against genital tract pathogens. All the quinolones were highly active against Neisseria gonorrhoeae. A-56619 had the lowest MICs against Chlamydia trachomatis (MIC range, 0.125 to 0.25 micrograms/ml) and Haemophilus ducreyi (MIC for 90% of isolates tested, 0.1 micrograms/ml).
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002692:Chlamydia trachomatis / Q000187:drug effects*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D024841:Fluoroquinolones; D006194:Gardnerella vaginalis / Q000187:drug effects; D005835:Genitalia / Q000382:microbiology; D006190:Haemophilus / Q000187:drug effects*; D006191:Haemophilus ducreyi / Q000187:drug effects; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D009174:Mycoplasma / Q000187:drug effects; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D009643:Norfloxacin / Q000494:pharmacology; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology; D014509:Ureaplasma / Q000187:drug effects
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D010078:Oxazines; D002939:Ciprofloxacin; C047225:difloxacin; D015242:Ofloxacin; D009643:Norfloxacin; C047224:sarafloxacin